Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 4/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108286 | 1.00 | ALDH1A1 (0.43) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL13134631 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL800959 | 0.89 | ALDH1A1 (0.43) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL10492407 | 0.80 | P2RY2 (0.41) | — | |
| SCHEMBL540156 | 0.80 | P2RY2 (0.41) | — | |
| SCHEMBL5580058 | 0.80 | LMNA (0.52) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL5505144 | 0.80 | LMNA (0.52) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL541102 | 0.80 | P2RY2 (0.41) | — | |
| SCHEMBL14829540 | 0.80 | LMNA (0.52) | ALDH1A1LMNAALBPOLBADRA1A | |
| SCHEMBL3952359 | 0.80 | P2RY2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | ALDH1A1 3122/4885LMNA 243/4885ALB 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.